BTIG Maintains Buy on Viking Therapeutics, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Justin Zelin has maintained a Buy rating on Viking Therapeutics (NASDAQ:VKTX) and increased the price target from $86 to $100.
March 15, 2024 | 4:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Justin Zelin reaffirmed a Buy rating on Viking Therapeutics and raised the price target from $86 to $100.
The increase in the price target by a reputable analyst suggests a strong confidence in Viking Therapeutics' future performance. This endorsement is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100